COVID-19 in heart transplant recipients.
Sepideh TaghaviHoda Raffiei JelodarAli RafatiAhmad AminMarzieh MirtajaddiniAhmad AminLeili ValizadehRazieh OmidvarMonireh KamaliSoroush NasehPublished in: Journal of cardiovascular and thoracic research (2022)
Introduction: After solid organ transplantation, patients require lifelong immunosuppressive medication, increasing susceptibility to COVID-19. We evaluated the clinical outcomes of heart transplant recipients in patients with COVID-19. Methods: We enrolled twenty-two COVID-19 cases of adult heart transplantation from February 2020 to September 2021. Results: The most common symptoms in patients were fever and myalgia. The death occurred in 3 (13.6 %). Conclusion: Although heart transplantation mortality may increase in the acute rejection phase concomitant with COVID-19, immunosuppressive dose reduction may not be necessary for all heart transplant patients with COVID-19.
Keyphrases
- coronavirus disease
- sars cov
- end stage renal disease
- heart failure
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- atrial fibrillation
- emergency department
- type diabetes
- liver failure
- cardiovascular disease
- physical activity
- cardiovascular events
- bone marrow
- depressive symptoms
- mesenchymal stem cells
- adverse drug